SummaryRMgm-654
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene mutation, Introduction of a transgene, Introduction of a transgene |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 21899698 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA 820cl1m1cl1 (RMgm-164) |
Other information parent line | P. berghei ANKA 820cl1m1cl1 (RMgm-164) is a reference ANKA mutant line which expresses GFP under control of a male and RFP under control of a female gametocyte specific promoter. This reference line does not contain a drug-selectable marker (PubMed: PMID: 19438517). |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | E. Laurentino, C.J. Janse, A.P. Waters |
Name Group/Department | Leiden Malaria Research Group |
Name Institute | Leiden University Medical Center |
City | Leiden |
Country | The Netherlands |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-654 |
Principal name | 1135cl1,cl2 |
Alternative name | Δfact-l gam 2c |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Normal numbers of female and male gametocytes are produced. Fertility of female gametes is comparable to wild type female gametes as shown by crossing with wild type male gametes. Male gametocytes showed delayed DNA replication and gamete formation. Male gamete fertility is strongly reduced |
Fertilization and ookinete | Normal numbers of female and male gametocytes are produced. Fertility of female gametes is comparable to wild type female gametes as shown by crossing with wild type male gametes. Male gametocytes showed delayed DNA replication and gamete formation. Male gamete fertility is strongly reduced, resulting in strongly reduced ookinete formation. |
Oocyst | Male gamete fertility is strongly reduced, resulting in strongly reduced ookinete formation. Residual ookinetes generated oocysts that arrested early in development and failed to enter sporogony. |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation BLAST-based homology searches with PBANKA_123220 identified clear homology to the eukaryotic SPT16 protein (e.g. 30% identity, 41% similarity to SPT16 of Saccharomyces cerevisiae) with an identical arrangement of the Rttp106-like, SPT16 and M24 peptidase domains. Attempts to disrupt the fact-l gene in P. berghei were unsuccessful (see RMgm-255), indicating an essential role of FACT-L for blood stage development/multiplication In the 'promoter-swap' mutant the promoter of fact-l is replaced by an 'asexual blood stage specific’ promoter that is silent in gametocytes (the promoter of PBANKA_140060). Transcription of fact-l in mutant gametocytes was down-regulated compared with wild-type gametocytes. Phenotype analyses of the promoter-swap mutant indicate that FACT-L plays an important role in the production of fertile male gametes. The promoter-swap mutant produced normal numbers of female and male gametocytes. Fertility of female gametes is comparable to wild type female gametes as shown by crossing with wild type male gametes. Male gametocytes showed delayed DNA replication and gamete formation. Male gamete fertility is strongly reduced, resulting in strongly reduced ookinete formation. Residual ookinetes generated oocysts that arrested early in development and failed to enter sporogony. In the same paper a successful 'promoter-swap' mutants are described in which the promoter of fact-l is replaced by the 'asexual blood stage specific’ promoter of PBANKA_091420 that is silent in gametocytes. These mutants are: Δfact-lgam1a, 1044 in cl15cy1; Δfactlgam 1b, 1076cl1, cl3 in 507cl2; Δfact-lgam 1c, 1134cl1,cl2 in 820cl1m1cl1. Other mutants |
top of page | |||||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1232200 | ||||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0517400 | ||||||||||||||||||||||||||
Gene product | FACT complex subunit SPT16, putative | ||||||||||||||||||||||||||
Gene product: Alternative name | FACT-L; FACT | ||||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||||
Short description of the mutation | 'promoter-swap' mutant; the promoter of fact-l replaced by the promoter of PBANKA_140060 | ||||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||||
Short description of the conditional mutagenesis | Not available | ||||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||||
Type of plasmid/construct | Plasmid double cross-over | ||||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||||
Additional remarks genetic modification | DNA constructs were generated to exchange or ‘swap’ the endogenous fact-l promoter with a promoter of a gene that was expected not to be transcribed in gametocytes (PBANKA_140060). Vector pL0001 (http://www.mr4.org) for integration via double-cross-over homologous recombination, was used as the backbone for four different promoter-swap constructs. This vector contains the dhfr-ts gene of Toxoplasma gondii under the control of the P. berghei dhfr-ts promoter as selectable marker cassette. Three subcloning steps were performed to generate the promoter-swap constructs: first, a 539 bp fragment located 2 kb upstream of fact-l, was PCR-amplified from genomic DNA using primer pair 3190/3191 (ggggtaccTACTATAACATGGTTTTGCC (F); ccaagcttAGGATAAAAACATAGGTGTG (R)). This fragment represents the left flanking target region and was cloned into the KpnI/HindIII restriction sites of pL0001. As the right flanking target region, a 623 bp fragment of the open reading frame of fact-l was PCR amplified using primer pair 3192/3193 (gctctagaTGAACTTTGTAAAAACAAGC (F); tccccgcggGAATTTTCAATGGTAGTTATCA (R)). This fragment was cloned into the SacII/XbaI restriction sites of the vector. Finally, a 2 kb fragment of the 5'UTR promoter region of PBANKA_140060 was amplified from genomic DNA using the primer pair 3196/3197 (CGgaattcATTCGATGTTTACATAATGAC (F); CGggatccCGAATTGACACCATTTTTCC (R) and cloned into the EcoRI/BamHI sites of the vector. The promoter-swap construct (pL1313) was linearized with KpnI/SacII before transfection. | ||||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
top of page |
top of page | |||||||||||||||||||
Type and details of transgene | |||||||||||||||||||
Is the transgene Plasmodium derived | Transgene: not Plasmodium | ||||||||||||||||||
Transgene name | RFP | ||||||||||||||||||
top of page | |||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||
Inducable system used | No | ||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||
Type of plasmid/construct | Plasmid double cross-over | ||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||
Selection (negative) procedure | 5-fluorocytosine (5-FC) | ||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||
top of page | |||||||||||||||||||
Other details transgene | |||||||||||||||||||
top of page | |||||||||||||||||||
Promoter | |||||||||||||||||||
Gene Model of Parasite | PBANKA_1319500 | ||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1455800 | ||||||||||||||||||
Gene product | LCCL domain-containing protein | ||||||||||||||||||
Gene product: Alternative name | LAP4; LCCL/lectin adhesive-like protein 4; CCp2 | ||||||||||||||||||
| |||||||||||||||||||
top of page | |||||||||||||||||||
3'-UTR | |||||||||||||||||||
Gene Model of Parasite | PBANKA_1359600 | ||||||||||||||||||
Gene product | transmission blocking target antigen precursor 6-cysteine protein | ||||||||||||||||||
Gene product: Alternative name | P48/45 | ||||||||||||||||||
| |||||||||||||||||||
Insertion/Replacement locus | |||||||||||||||||||
Replacement / Insertion | Replacement locus | ||||||||||||||||||
Gene Model of Parasite | PBANKA_0306000 | ||||||||||||||||||
Gene product | 6-cysteine protein | ||||||||||||||||||
Gene product: Alternative name | 230p, P230p | ||||||||||||||||||
| |||||||||||||||||||
top of page |
top of page | |||||||||||||||||||
Type and details of transgene | |||||||||||||||||||
Is the transgene Plasmodium derived | Transgene: not Plasmodium | ||||||||||||||||||
Transgene name | GFP (gfp-mut3) | ||||||||||||||||||
top of page | |||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||
Inducable system used | No | ||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||
Type of plasmid/construct | Plasmid double cross-over | ||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||
Selection (negative) procedure | 5-fluorocytosine (5-FC) | ||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||
top of page | |||||||||||||||||||
Other details transgene | |||||||||||||||||||
top of page | |||||||||||||||||||
Promoter | |||||||||||||||||||
Gene Model of Parasite | PBANKA_0416100 | ||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0905300 | ||||||||||||||||||
Gene product | dynein heavy chain, putative | ||||||||||||||||||
Gene product: Alternative name | |||||||||||||||||||
| |||||||||||||||||||
top of page | |||||||||||||||||||
3'-UTR | |||||||||||||||||||
Gene Model of Parasite | PBANKA_1010600 | ||||||||||||||||||
Gene product | calmodulin, putative | ||||||||||||||||||
Gene product: Alternative name | cam | ||||||||||||||||||
| |||||||||||||||||||
Insertion/Replacement locus | |||||||||||||||||||
Replacement / Insertion | Replacement locus | ||||||||||||||||||
Gene Model of Parasite | PBANKA_0306000 | ||||||||||||||||||
Gene product | 6-cysteine protein | ||||||||||||||||||
Gene product: Alternative name | 230p; P230p | ||||||||||||||||||
| |||||||||||||||||||
top of page |